NVS

NOVARTIS AG-SPONSORED ADR (NVS) Stock Price

Closed
NVS
$150.12
-$1.03(-0.68%)

Content updated: 2026-11-22 22:47:59

Yesterday's Close
$151.15
Today's Open
$152.00
Today's High
$152.52
Today's Low
$150.12
Volume
1.54M shares
52-Week Range
$137.03-$166.26

As of 2026-11-22 22:47:59, NOVARTIS AG-SPONSORED ADR (NVS) was quoted at $150.12, a change of -$1.03 (-0.68%) from the previous close. The day's range was $150.12–$152.52, and the 52-week range was $137.03–$166.26.

Why Is NOVARTIS AG-SPONSORED ADR (NVS) Stock Falling?

AI Stock Price Analysis

Content updated: 2026-11-20 21:10:34

Novartis ADR opened lower, briefly recovered to $153.18 and then faded to $151.25 near the bottom of the day's range, down 2.58% from the prior close on steady volume. Its mid-term outlook update narrowed the sales growth guide to about 5% through 2031, prompting a reassessment of the medium-term growth path.

Past 1W-7.28%Period Low $150.23Period High $163.25
Past 1M-2.87%Period Low $149.17Period High $165.96
Past 3M-4.24%Period Low $137.00Period High $165.96
Past 1Y+19.51%Period Low $125.88Period High $170.46

About NOVARTIS AG-SPONSORED ADR (NVS)

Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. Its product portfolio is heavily focused on innovative prescription medicines, especially oncology, immunology, neuroscience, and cardiovascular diseases, supplemented by established older brands and a wide range of specialized therapies. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.
Ticker / Exchanges
NVS / NYSE
Industry / Sector
Drug Manufacturers - General / Healthcare
CEO
Vasant Narasimhan
Headquarters
Basel,BS,CH
Official Website
https://www.novartis.com
Listing Date
1996-11-07

Recent Company Events

  • 2027-02-03
    Earnings Report · ExpectedOn 2027-02-03, the 2026/Q4 earnings report is expected to be released.

NOVARTIS AG-SPONSORED ADR (NVS) Derivatives Trading

Stocks

Trade U.S., Hong Kong, Japanese, and South Korean stocks directly. Selected U.S., Hong Kong, and South Korean stocks support 24/7 trading. You hold actual shares. Corporate actions such as dividends and stock splits are handled according to market rules.

CFD

Trade stock price movements through CFDs without holding the underlying shares. CFDs support long and short positions and leveraged trading. Be aware of spreads, trading fees, overnight fees, and liquidation risk.

NOVARTIS AG-SPONSORED ADR (NVS) Company Financials

Valuation and Shares

Market Cap
$284.14B
P/E Ratio (TTM)
28.71
P/B Ratio
7.63
Shares Outstanding
1.88B shares
Float Shares
1.84B shares
Dividend Yield (TTM)
3.15%

Latest Reported Financials

2026 Q3 Financials

Report Release Date: 2026-10-27

Operating Revenue (Actual)

$14.52B

Same Period Last Year: +1.14%

Earnings per Share (Actual)

$2.46

Same Period Last Year: +9.33%

Financials · Actuals

Actual Value2022/Annual2023/Annual2024/Annual2025/Annual
Revenue$43.46B$46.66B$51.72B$56.67B
Net Profit$6.95B$14.85B$11.94B$13.98B
Operating Cash Flow$14.23B$14.45B$17.61B$19.14B

NVS FAQ

What is the current stock price of NOVARTIS AG-SPONSORED ADR (NVS)?

x
As of 2026-11-22 22:47 (UTC+8), the latest available quote for NOVARTIS AG-SPONSORED ADR (NVS) is $150.12 USD, with a change of -$1.03 USD (-0.68%) from the previous trading day's close. Current market status: Closed.

Which exchange is NVS listed on?

x

How has NOVARTIS AG-SPONSORED ADR stock performed over the past month?

x

What is the market cap of NOVARTIS AG-SPONSORED ADR?

x

What are NOVARTIS AG-SPONSORED ADR's latest financial results?

x

What factors may affect the stock price of NOVARTIS AG-SPONSORED ADR (NVS)?

x

Other Trading Markets

Risk Warning

The stock market involves a high level of risk and price volatility. The value of your investment may increase or decrease, and you may not recover the full amount invested. Past performance is not a reliable indicator of future results. Before making any investment decisions, you should carefully assess your investment experience, financial situation, investment objectives, and risk tolerance, and conduct your own research. Where appropriate, consult an independent financial adviser.

Disclaimer

The content on this page is provided for informational purposes only and does not constitute investment advice, financial advice, or trading recommendations. Gate shall not be held liable for any loss or damage resulting from such financial decisions. Further, take note that Gate may not be able to provide full service in certain markets and jurisdictions, including but not limited to the United States of America, Canada, Iran, and Cuba. For more information on Restricted Locations, please refer to the User Agreement.